AbbVie Inc. closed 15.13% below its 52-week high of $218.66, which the company reached on March 10th.

AbbVie is strutting into 2025 like it owns the lab, thanks to a performance cocktail of smart acquisitions, clinical wins, ...

Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics ...

AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...

AbbVie’s stock faced a chilly reception on May 6, plunging 4.55% and ending the day at $187.15. Despite strong fundamentals ...

After a two-year surge of 53%, the stock market has been taken for a wild ride in 2025, driven by uncertainties surrounding ...

Ironwood Pharmaceuticals, Inc.’s IRWD share price has surged by 5.57%, which has investors questioning if this is right time ...

AbbVie ( NYSE: ABBV) shares snapped seven straight sessions of gains, as the stock was down 0.9% at $193.40 on Thursday. The maker of Humira arthritis therapy added over 12% in the preceding seven ...

AbbVie wins FDA approval for Rinvoq in giant cell arteritis after strong Phase 3 results and a 57.2% year-over-year sales ...

The Graham number is often used in isolation, but in fact it is only one part of a check list for choosing defensive stocks that he laid out in Chapter 14 of The Intelligent Investor. The analysis ...

Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 10 years ago, it would be worth $300.66 today based on a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.